These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 32879848)
1. Mutational analysis of Tripathi K; Goel A; Singhai A; Garg M World J Clin Oncol; 2020 Aug; 11(8):614-628. PubMed ID: 32879848 [TBL] [Abstract][Full Text] [Related]
2. Activation of RAS family genes in urothelial carcinoma. Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097 [TBL] [Abstract][Full Text] [Related]
3. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Berger DH; Chang H; Wood M; Huang L; Heath CW; Lehman T; Ruggeri BA Cancer; 1999 Jan; 85(2):326-32. PubMed ID: 10023699 [TBL] [Abstract][Full Text] [Related]
4. Modified mismatch polymerase chain reaction-restriction fragment length polymorphism detected mutations in codon 12 and 13 of exon 2 of K- Faleel FD; Zoysa MI; Lokuhetti MD; Gunawardena YI; Chandrasekharan VN; Dassanayake RS J Cancer Res Ther; 2016; 12(4):1272-1277. PubMed ID: 28169239 [TBL] [Abstract][Full Text] [Related]
5. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue. Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783 [TBL] [Abstract][Full Text] [Related]
6. Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder. Tripathi K; Goel A; Singhai A; Garg M Mol Biol Rep; 2021 Mar; 48(3):2183-2199. PubMed ID: 33620658 [TBL] [Abstract][Full Text] [Related]
7. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772 [TBL] [Abstract][Full Text] [Related]
8. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. Feng Z; Hu W; Chen JX; Pao A; Li H; Rom W; Hung MC; Tang MS J Natl Cancer Inst; 2002 Oct; 94(20):1527-36. PubMed ID: 12381705 [TBL] [Abstract][Full Text] [Related]
9. Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. Grimmond SM; Raghavan D; Russell PJ Urol Res; 1992; 20(2):121-6. PubMed ID: 1553789 [TBL] [Abstract][Full Text] [Related]
10. Mutational activation of k-ras oncogene in human breast-tumors. Koffa M; Malamoumitsi V; Agnantis N; Spandidos D Int J Oncol; 1994 Mar; 4(3):573-6. PubMed ID: 21566961 [TBL] [Abstract][Full Text] [Related]
11. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Knowles MA; Williamson M Cancer Res; 1993 Jan; 53(1):133-9. PubMed ID: 8093230 [TBL] [Abstract][Full Text] [Related]
12. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992 [TBL] [Abstract][Full Text] [Related]
13. Detection of point mutations at codon 12 of KI-ras in ophthalmic pterygia. Detorakis ET; Zafiropoulos A; Arvanitis DA; Spandidos DA Eye (Lond); 2005 Feb; 19(2):210-4. PubMed ID: 15232598 [TBL] [Abstract][Full Text] [Related]
14. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572 [TBL] [Abstract][Full Text] [Related]
15. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Nishikawa T; Maemura K; Hirata I; Matsuse R; Morikawa H; Toshina K; Murano M; Hashimoto K; Nakagawa Y; Saitoh O; Uchida K; Katsu K Clin Chim Acta; 2002 Apr; 318(1-2):107-12. PubMed ID: 11880119 [TBL] [Abstract][Full Text] [Related]
16. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Dieterle CP; Conzelmann M; Linnemann U; Berger MR Clin Cancer Res; 2004 Jan; 10(2):641-50. PubMed ID: 14760087 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691 [TBL] [Abstract][Full Text] [Related]
18. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Przybojewska B; Jagiello A; Jalmuzna P Cancer Genet Cytogenet; 2000 Aug; 121(1):73-7. PubMed ID: 10958945 [TBL] [Abstract][Full Text] [Related]
19. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Saito S; Hata M; Fukuyama R; Sakai K; Kudoh J; Tazaki H; Shimizu N Int J Urol; 1997 Mar; 4(2):178-85. PubMed ID: 9179693 [TBL] [Abstract][Full Text] [Related]
20. A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61. Hong SJ; Lee T; Park YS; Lee KO; Chung BH; Lee SH Yonsei Med J; 1996 Dec; 37(6):371-9. PubMed ID: 9048488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]